Primary prevention of sudden cardiac death in hypertrophic cardiomyopathy

ESC CardioMed ◽  
2018 ◽  
pp. 2348-2351
Author(s):  
Barry J. Maron ◽  
Martin S. Maron

Hypertrophic cardiomyopathy (HCM) has been regarded as the most common non-trauma-related cause of sudden cardiac death (SCD) in young people, including competitive athletes. The traditional clinical profile of HCM patients at highest risk of SCD is largely comprised of young asymptomatic patients, particularly children and adolescents. Prophylactic drug treatment to prevent SCD is ineffective and obsolete whereas the introduction of implantable cardioverter defibrillators (ICD) has changed the clinical course and natural history of the disease. The ICDs are largely responsible for reducing HCM-related mortality to 0.5%/year and have been shown to be effective despite the often complex HCM phenotype, including extreme and diverse patterns of left ventricular hypertrophy, dynamic subaortic obstruction, microvascular ischaemia, and diastolic dysfunction. An important principle related to ICD decisions in HCM patients surrounds the unpredictable nature of the arrhythmic substrate, often associated with substantial delays of 5–10 years between implant and initial intervention. Selection of patients most likely to benefit from primary prevention ICD therapy is based on non-invasive testing including echocardiography or cardiac magnetic resonance imaging, history taking, exercise testing, and ambulatory electrocardiogram (ECG). Conventional risk markers are (1) family history (one or more HCM-related SCDs in close relatives); (2) recent unexplained syncope; (3) multiple repetitive (or prolonged) non-sustained ventricular tachycardia on ambulatory ECG; (4) massive left ventricular hypertrophy (wall thickness ≥30 mm); and (5) hypotensive blood pressure response to exercise, although this is not a sole indication for ICD implants. ICD decisions within current risk stratification guidelines can be challenging, particularly in patients with just one risk factor or when available evidence is ambiguous or insufficient to assign SCD risk level with confidence.

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
D Cortez ◽  
H Morrell

Abstract Background The most common cause of sudden cardiac death in the United State of America is hypertrophic cardiomyopathy, while other causes such as left ventricular hypertrophy, ion-channelopathies, and other causes are also significant. Screening programs typically involve electrocardiograms with mainly false positive results. Little data regarding EKG and echocardiographic screening combined have been published. Methods During 2016–2019, over 15000 patients were screened by the Heartfelt Cardiac screening program. Screening electrocardiograms and echocardiograms including parasternal short/long axis, 4-chamber views, coronary assessment with color doppler and subcostal views with color doppler for assessment of septal defects, were performed. Results 15,329 patients were screened under 35 years of age, mean age 17 years, with 36 hypertrophic cardiomyopathy patients, 61 borderline left ventricular hypertrophy patients noted, 30 patients with left ventricular dysfunction were noted, 47 patients with mitral valve prolapse, 27 patients with atrial septal defects, 39 patients with Wolf-Parkinson-White, 21patients with ideopathic dilated cardiomyopathy were discovered. Screening electrocardiography was helpful for Wolf-Parkinson-White identification, while echocardiogram was most helpful for detection of the above other defects. Screening EKG only identified 45% of those patients with myocardial disease (per above) with the modified Seattle Screening and ESC screening criteria. Conclusion Screening echocardiogram adds value for screening athletes under 35 years at risk for sudden cardiac death. Consideration of cost-effective echo screening should be considered as part of routine screening.


2018 ◽  
Vol 8 (1) ◽  
Author(s):  
Gabrielle Norrish ◽  
Juan Pablo Kaski

Hypertrophic cardiomyopathy (HCM) is defined as left ventricular hypertrophy in the absence of loading conditions sufficient to cause the observed abnormality. The true prevalence in childhood is unknown; the aetiology is more heterogeneous than that seen in adult populations, and includes inborn errors of metabolism, malformation syndromes and neuromuscular syndromes. However, one of the greatest clinical challenges in managing young patients with HCM is identifying those at greatest risk of sudden cardiac death.


2010 ◽  
Vol 142 (1) ◽  
pp. 80-86 ◽  
Author(s):  
Masato Nishimura ◽  
Toshiko Tokoro ◽  
Masasya Nishida ◽  
Tetsuya Hashimoto ◽  
Hiroyuki Kobayashi ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document